158 related articles for article (PubMed ID: 28187492)
41. Precision Medicine Versus Evidence-Based Medicine: Individual Treatment Effect Versus Average Treatment Effect.
Blackstone EH
Circulation; 2019 Oct; 140(15):1236-1238. PubMed ID: 31589490
[No Abstract] [Full Text] [Related]
42. Warfarin-amiodarone drug-drug interactions: determination of [I](u)/K(I,u) for amiodarone and its plasma metabolites.
McDonald MG; Au NT; Wittkowsky AK; Rettie AE
Clin Pharmacol Ther; 2012 Apr; 91(4):709-17. PubMed ID: 22398967
[TBL] [Abstract][Full Text] [Related]
43. Potential clinical and economic outcomes of CYP2C9 and VKORC1 genotype-guided dosing in patients starting warfarin therapy.
You JH; Tsui KK; Wong RS; Cheng G
Clin Pharmacol Ther; 2009 Nov; 86(5):540-7. PubMed ID: 19571807
[TBL] [Abstract][Full Text] [Related]
44. Hospitalization for hemorrhage among warfarin recipients prescribed amiodarone.
Lam J; Gomes T; Juurlink DN; Mamdani MM; Pullenayegum EM; Kearon C; Spencer FA; Paterson M; Zheng H; Holbrook AM
Am J Cardiol; 2013 Aug; 112(3):420-3. PubMed ID: 23664078
[TBL] [Abstract][Full Text] [Related]
45. Using simulation and optimization approach to improve outcome through warfarin precision treatment.
Chi CL; He L; Ravvaz K; Weissert J; Tonellato PJ
Pac Symp Biocomput; 2018; 23():412-423. PubMed ID: 29218901
[TBL] [Abstract][Full Text] [Related]
46. Economic evaluation of pharmacogenomic-guided warfarin treatment for elderly Croatian atrial fibrillation patients with ischemic stroke.
Mitropoulou C; Fragoulakis V; Bozina N; Vozikis A; Supe S; Bozina T; Poljakovic Z; van Schaik RH; Patrinos GP
Pharmacogenomics; 2015 Jan; 16(2):137-48. PubMed ID: 25616100
[TBL] [Abstract][Full Text] [Related]
47. Institutional profile: University of Florida and Shands Hospital Personalized Medicine Program: clinical implementation of pharmacogenetics.
Johnson JA; Elsey AR; Clare-Salzler MJ; Nessl D; Conlon M; Nelson DR
Pharmacogenomics; 2013 May; 14(7):723-6. PubMed ID: 23651020
[TBL] [Abstract][Full Text] [Related]
48. Pharmacogenomic biomarkers: validation needed for both the molecular genetic mechanism and clinical effect.
Sadee W
Pharmacogenomics; 2011 May; 12(5):675-80. PubMed ID: 21619429
[TBL] [Abstract][Full Text] [Related]
49. Is personalized medicine a dream or a reality?
Morse BL; Kim RB
Crit Rev Clin Lab Sci; 2015 Feb; 52(1):1-11. PubMed ID: 25181036
[TBL] [Abstract][Full Text] [Related]
50. On study designs and hypotheses for clinical trials with predictive biomarkers.
Shih WJ; Lin Y
Contemp Clin Trials; 2017 Nov; 62():140-145. PubMed ID: 28838813
[TBL] [Abstract][Full Text] [Related]
51. Will there be a role for genotyping in warfarin therapy?
Gandara E; Wells PS
Curr Opin Hematol; 2010 Sep; 17(5):439-43. PubMed ID: 20601874
[TBL] [Abstract][Full Text] [Related]
52. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation.
Anderson JL; Horne BD; Stevens SM; Grove AS; Barton S; Nicholas ZP; Kahn SF; May HT; Samuelson KM; Muhlestein JB; Carlquist JF;
Circulation; 2007 Nov; 116(22):2563-70. PubMed ID: 17989110
[TBL] [Abstract][Full Text] [Related]
53. A Tutorial for Pharmacogenomics Implementation Through End-to-End Clinical Decision Support Based on Ten Years of Experience from PREDICT.
Liu M; Vnencak-Jones CL; Roland BP; Gatto CL; Mathe JL; Just SL; Peterson JF; Van Driest SL; Weitkamp AO
Clin Pharmacol Ther; 2021 Jan; 109(1):101-115. PubMed ID: 33048353
[TBL] [Abstract][Full Text] [Related]
54. Identifying Drug-Drug Interactions by Data Mining: A Pilot Study of Warfarin-Associated Drug Interactions.
Hansen PW; Clemmensen L; Sehested TS; Fosbøl EL; Torp-Pedersen C; Køber L; Gislason GH; Andersson C
Circ Cardiovasc Qual Outcomes; 2016 Nov; 9(6):621-628. PubMed ID: 28263937
[TBL] [Abstract][Full Text] [Related]
55. Management of warfarin-related intracerebral hemorrhage.
Freeman WD; Aguilar MI
Expert Rev Neurother; 2008 Feb; 8(2):271-90. PubMed ID: 18271712
[TBL] [Abstract][Full Text] [Related]
56. [Which of algorithms of warfarin dosing based on results of pharmacogenetic testing is suitable for patients in Russia].
Sychev DA; Antonov IM; Kropacheva ES; Panchenko EP
Kardiologiia; 2010; 50(4):35-7. PubMed ID: 20459419
[TBL] [Abstract][Full Text] [Related]
57. Introduction: Personalized medicine: what is it and what are the challenges?
Sigman M
Fertil Steril; 2018 Jun; 109(6):944-945. PubMed ID: 29935651
[TBL] [Abstract][Full Text] [Related]
58. Pharmacogenetics in Cardiovascular Medicine.
Tuteja S; Limdi N
Curr Genet Med Rep; 2016 Sep; 4(3):119-129. PubMed ID: 29057167
[TBL] [Abstract][Full Text] [Related]
59. Tabula Rasa HealthCare company profile: involvement in pharmacogenomic and personalized medicine research.
Matos A; Dow P; Bingham JM; Michaud V; Lesko LJ; Knowlton CH; Turgeon J
Pharmacogenomics; 2021 Aug; 22(12):731-735. PubMed ID: 34284600
[No Abstract] [Full Text] [Related]
60. Institutional profile. UNC Institute for Pharmacogenomics and Individualized Therapy: interdisciplinary research for individual care.
Rakhra-Burris TK; Auman JT; Deverka P; Dressler LG; Evans JP; Goldberg RM; Havener TM; Hoskins JM; Jonas DE; Long KM; Motsinger-Reif AA; Irvin WJ; Richards KL; Roederer MW; Valgus JM; Riper Mv; Vernon JA; Zamboni WC; Wagner MJ; Walko CM; Weck KE; Wiltshire T; McLeod HL
Pharmacogenomics; 2010 Jan; 11(1):13-21. PubMed ID: 20017668
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
